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Referent TB control indicators and targets 
 
A number of targets have been set and commitments made with direct 
relevance to TB Control in the African continent over the past 10 years.  
 
In 1991, the World Health Assembly (WHA) adopted a resolution urging 
countries to detect 70% of new smear-positive TB cases arising annually, and 
successfully treating 85% of them by 2005. These targets remain relevant for 
all counties that have not yet attained these targets. 
 
In 2000, World leaders established the Millennium Development Goals that 
seek to halt by 2015 and begin to reverse the incidence of HIV/AIDS, malaria 
and other major diseases. Incidence, prevalence and death rates associated 
with tuberculosis, and proportion of tuberculosis cases detected and cured 
under DOTS as specified by the WHA were re-iterated. By way of 
operationalising the TB related MDG targets, the Stop TB Partnership 
confirmed the WHA targets for case detection and successful treatment. In 
addition, it called for 50% reduction in global TB burden relative to 1990 levels 
by 2015, and elimination of TB by 2050. 
 
In April 2001, the African Heads of State and Government adopted a 
declaration on HIV/AIDS, Tuberculosis and Other related Infectious Diseases 
(ORID) calling upon member states to strive to allocate 15% of national 
budgets to the improvement of the health sector, and to allocate appropriate 
and adequate portions of this amount for the fight against HIV/AIDS, TB and 
ORID.  
  
Confirming the gravity of the TB epidemic in Africa, the 55th session of the 
Ministers of Health of the WHO African Region (2005) declared TB an 
emergency in the Region calling upon member states to implement urgent 
and extra-ordinary actions to rapidly improve tuberculosis case detection and 
treatment success-rates; and accelerate implementation of interventions to 
combat the TB/HIV epidemic, including increased access to ARVs by doubly-
infected patients; 
 
In May 2006, Heads of State and Government of the African Union held a 
Special Summit on HIV/AIDS, Tuberculosis and Malaria, to review the status 
of implementation of the 2000 and 2001 Declarations and Frameworks of 
action to Roll Back Malaria, and the 2001 Abuja Summit on HIV/AIDS, TB and 
ORID.  They adopted the “Abuja Call for Accelerated Action towards Universal 
Access to HIV/AIDS, Tuberculosis and Malaria services” that pledged 
collective dedication to a comprehensive remedial effort anchored on an 
implementation mechanism that responds to the continent’s health and 
developmental challenges and imperatives. The Summit reaffirmed previous 
global and regional targets for TB control as well as called for universal 
MIN/Sp/AU/CAMH3/6 TB 
Page 2 
access to TB prevention, treatment, care and support services, including of 
key TB-HIV interventions.  
 
Despite the progress in tuberculosis control, northern African countries have 
failed in achieving the global targets for tuberculosis control. While DOTS has 
expanded, covering 94% of the regional population and treatment success is 
high (82%), the case detection rate is only 44%. To improve case detection, 
the regional plan to Stop TB was developed as part of the global plan 2006–
2015. The budgetary need for the period of 2006 to 2015 indicated in the Plan 
is US$ 3.1 billion in the WHO/EMRO Region. Support to countries was 
enhanced and partnership development promoted. 
 
This Report is prepared at the request of the 2006 Special Summit and the 
AU Conference of Ministers of Health.  It reviews the status towards 
achievement of the TB targets as specified in the Abuja commitments and the 
MDGs.  
 
Status of TB Control indicators and targets 
 
Leadership at National, Regional and Continental Levels 
 
The 2006 Abuja Call for Universal Access to ATM services is the most recent 
indication of the continent’s growing political leadership for TB Control in the 
Region. It builds on and creates a supportive political environment for the 
quantitative pursuance of the World Health Assembly, MDG, Abuja 2001, and 
Maputo 2005 TB control targets.  Political leadership has also been 
demonstrated through declaration of TB as national emergencies by at least 
18 countries in the African Region; the adoption of a Regional Strategy to 
combat the TB/HIV epidemic by the 57th session of the Regional Committee 
for Africa in 2007 and other related declarations by Regional Economic 
Communities (RECs), and Health Communities. 
 
The stated commitment not withstanding, national financing of health and TB 
Control programmes remains insufficient. Only two countries have achieved 
the 2001 pledge to allocate at least 15% of national budgets to the 
improvement of the health sector.  Furthermore, a later call to allocate 34USD 
per capita for health is yet to be adopted by the majority of countries. 
 
Estimated Prevalence, incidence and death rates 
 
Estimated TB prevalence, incidence and death rates all continue to increase 
in most countries. Notification rates have risen from 82 per 100,000 
population in 1990 to 160 in 2006. Despite an apparent stabilisation and 
decline in overall TB globally and in the African Region, at this rate, the MDG 
targets for TB incidence and prevalence are unlikely to be achieved at 
regional level. In Eastern Mediterranean Region, incidence rates are higher 
for Djibouti, Somalia and Sudan than in the other countries in northern Africa. 
 
However, according to the 2008 WHO Global TB Report, by the end of 2006, 
Comoros, Ghana, Mali, Mauritius, Sao Tome & Principe and Seychelles had 
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already halted and started to reverse overall and smear positive TB incidence 
as specified in the core MDG targets (without applying the reference to 1990 
rates as specified by the Stop TB Partnership in quantifying the MDG targets).  
 
A further 6 countries, namely, Angola, Benin, Cape Verde, Eritrea, Guinea 
Bissau and Niger had already halted and started to reverse estimated TB 
prevalence, while four countries, namely, Angola, Comoros, Sao Tome & 
Principe and Seychelles had already halted and started to reverse death 
rates. 
 
Status of case detection and treatment success rates 
 
Case detection rate: 
 
While increasing overtime during the past five years, at 46%, new smear 
positive case detection rate for the African Region is significantly below the 
70% target set by the WHA, MDGs and the Special Summit. The region is 
only achieving 65% of the target.  Mediterranean countries of North Africa are 
also performing better.  
 
However, according to the 2008 WHO TB Report, 12 countries1 had met the 
70% case detection target, and 8 countries2 had achieved the 85% treatment-
success target. Only 3 countries (Algeria, Benin and Tunisia) had met both 
targets. 
 
Treatment Success Rates 
 
Treatment success rate has been increasing progressively since 1999. 
Nevertheless, at 76%, it still falls short of the 85% target. The region’s 
performance is only 89% of the set target.   Based on treatment outcomes for 
patients enrolled in 2005, only eight countries from the Region3 had reached 
the target.  This compares to two countries for 2001 patient cohort, three 
countries for 2002 cohort, four countries for 2003 cohort and eight countries 
for 2004 cohort.  A further four countries4 were making good progress and 
had attained treatment success rates of 80% and above.  In the EMRO 
African countries, success rates are generally above 76% except where 
records were not available. 
 
Drug Resistant TB 
 
Drug resistant TB, especially multi-drug resistant TB, is widely prevalent than 
previously known.  Twenty-six countries from the region reported a total of 
8,624 multi-drug resistant TB (MDR-TB) cases during 2007 while four 
countries (Botswana, Lesotho, Mozambique and South Africa (99.1% of the 
                                                
1 Algeria, Angola, Benin, Botswana, Cameroon, Kenya, Lesotho, Madagascar, Namibia, and South 
Africa 
2 Algeria, Benin, Comoros, DR Congo, Eritrea, Gambia, Mauritius and Sierra Leone 
3 Algeria, Benin, Democratic Republic of Congo, Eritrea, Gambia,  Mauritius and  Sierra Leone 
4 Kenya, Rwanda, United Republic of Tanzania and Zambia 
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cases)) reported a total of 541 Extensively Drug Resistant TB cases (XDR-
TB) cases during the same period. 
 
In terms of capability to diagnose MDR TB, there were still 10 Member States 
without this capability by the end of 2007.  
 
Of the 26 countries that reported at least a case of MDR or XDR-TB during 
2007, only 17 countries (65.4%) have an organized treatment programme for 
these cases despite the availability of a Stop TB Partnership global facility for 
accessing concessionary priced second line drugs by DOTS based TB 
Control programmes. Only 9 countries had successfully applied to this facility 
by February 2008. 
 
Status of implementation of TB/HIV Interventions 
 
During 2006 in the Africa Region, only 22% of notified cases were tested for 
HIV, compared to the 100% set by the Special Summit. However, this 
represents a 100% increase in coverage compared to 11.2% for 2005.  
 
Of those who tested positive, 37.1% were started on Anti-Retroviral Therapy 
(ART), increasing from 27.3% in 2005. Again this is far less than the 100% 
target. At this rate, the region is unlikely to reach the 100% target for both 
indicators by 2010.  
 
However, 11 countries5 recorded significant gains in ART coverage compared 
to the previous year.  The best results ranged from 30.8% in Rwanda to 
56.9% in Malawi. Furthermore, overall, 89.1% of HIV positive TB patients 
were started on Co-trimoxazole preventive therapy (CPT), a 23.4% increase 
compared to 72.2% in 2005. At this rate, Universal Access to CPT for dually 
infected persons is likely to be achieved by 2010.  
 
Access to essential anti-TB medicines 
 
Availability of first line anti-TB drugs has improved tremendously. By the end 
of December 2007, all 36 eligible countries from the Africa region that applied 
to the GDF secured first line anti-TB drug grants, including pediatric 
formulations for some countries.  
 
The increased availability notwithstanding, of the 42 countries that reported, 
only 69% maintained uninterrupted supply of first line anti-TB drugs at both 
the central and peripheral levels. As stated under drug resistant TB section 
above, only 65.4% of countries with reported MDR-TB cases had organized 
treatment programmes for those cases, and only 9 countries6 had taken steps 
to access concessionary priced second line drugs from the global facility of 
the Stop TB Partnership for such programmes.  
 
                                                
5 Benin, Cote D’Ivoire, DRC, Guinea Bissau, Kenya, Malawi, Mauritius, Mozambique, Rwanda, South 
Africa and Zambia 
6 Burkina Faso, DRC, Guinea Conakry, Kenya, Lesotho, Mozambique, Rwanda, Tanzania (pre-





It is not feasible to accurately determine levels of national financing for TB 
Control as TB funding is not earmarked within the general primary health care 
services. It is however evident that only two countries have attained the 15% 
allocation of national budgets to health as pledged in the 2001 Abuja 
declaration. 
 
At the same time, external funding for TB control activities has increased 
significantly. The Global Fund to Fight AIDS, TB and Malaria (GFATM) has 
been the single most important source of additional funding for TB control. 
Approximately 953 million USD (37% of total approved GFATM grants) has 
been approved for TB Control in the region from 2002-2007.   
 
However, the increased flow has not been marched by timely spending and 
increased case detection and treatment success rates in the majority of 




Tuberculosis control in Africa has progressed in the last decade but the 
continent still lags behind on major TB Control targets. Financial resources, 
traditionally a bottleneck for NTPs till the 2000’s, is no longer a major factor as 
GFATM grants, GDF grants (for standard TB treatment), GLC support (for 
drug resistant TB), bilateral donors support and several Partnership 
mechanisms provide technical and financial assistance to cover most needs. 
In order to achieve Universal Access by 2010 and the MDG targets by 2015, 
much remains to be done, especially to: 
 
 Increase treatment success rate for smear positive TB cases: 
through implementation of initiatives to reduce preventable 
unfavourable treatment outcomes such as patient default, transfer out 
and HIV/AIDS related TB deaths  
 
 Increase case detection rates: through development and 
strengthening of laboratory infrastructure, public private partnerships in 
the delivery of TB services and expanded institutional and community 
DOTS services. 
 
 Detect, treat and prevent Drug resistant TB: through surveillance, 
development of culture and DST capability for first line anti-TB drugs, 
and programmatic management of drug resistant TB cases as part of 
routine NTP activities 
  
 Scale up TB/HIV collaborative activities: especially HIV testing 
among TB patients, Co-trimoxazole and other preventive therapy, and 




 Address Health Systems Components that affect TB Control 
(laboratory networks, personnel, surveillance, supply systems and 




The following recommendations are made: 
 
i. All countries to periodically review their TB Control performance 
with regard to the WHA, MDG and Abuja targets and develop 
strategies to accelerate their attainment 
 
ii. Member states to decentralize and strengthen TB laboratory 
services in the public and private sectors to improve case 
detection and ensure quality assured laboratory services in 
pursuit of Universal Access to such services.  
 
iii. The African Union to advocate with national governments in the 
10 countries without local capability for TB culture and drug 
susceptibility testing for first line anti-TB drugs to establish this 
capacity in order to facilitate diagnosis and treatment of MDR-
TB cases 
 
iv. National TB Control Programmes to prioritize implementation of 
strategies to expand DOTS diagnosis and treatment services 
with a view to rapidly move towards the WHA, MDG, Abuja and 
Regional Committee targets for treatment success and case 
detection. This includes strengthening the capacity of the Health 
Systems to suspect and diagnose Tuberculosis, and to reduce 
treatment failures, treatment defaulters and transfer outs. 
 
v. All countries with generalized HIV epidemic (5% or higher) in the 
general population to programme and implement in full the 
Regional Strategy for controlling TB-HIV with particular 
emphasis on universal access to HIV testing for TB patients, 
ART for eligible HIV positive patients and other interventions to 
reduce the burden of TB on People Living with HIV & AIDS, and 
reduce the burden of HIV &AIDS on dually infected TB patients.                                                               
 
vi.  Member states to allocate sufficient resources to ensure 
uninterrupted supply of first line anti-TB drugs at central and 
peripheral levels, including adequate buffer stocks at the various 
levels.  
 
vii. For drug resistant TB cases, national programmes to determine 
the burden of MDR-TB and initiate treatment programmes for all 
confirmed cases. National programmes should also mobilize 
sufficient quality assured second line drugs including 
concessionary priced drugs through the Stop TB Partnership 




viii. Member states to respect the pledge to allocate at least 15% of 
the national budget to health development and allocate a 
sufficient amount of that for delivery for TB control interventions.  
Further, Member States to timely expend approved GFATM 
grants and submit proposals for more funding to meet funding 
gaps for scale up of activities towards universal access. 
 




1.1 TB CONTROL TARGETS: 
 
1.1.1 World Health Assembly target: 
 
In 1991, all WHO member states adopted a World Health Assembly (WHA) 
resolution7 setting two targets for global TB control to be reached by 2000: to 
detect 70% of new smear-positive TB cases arising annually, and to 
successfully treat 85% of these cases. When it became apparent that the 
year 2000 targets would not be met on time, the WHA postponed the target 
date to 2005. By 2005 only a small number of countries had attained the 
targets. Nevertheless, the WHA recommended that all countries continue 
pursuing these operational targets as they are essential to achieve impact on 
TB epidemiology. 
  
1.1.2 Millennium Development Goal targets and indicators for TB 
Control: 
 
Responding to the world's main development challenges, World leaders 
established in 2000 the Millennium Development Goals with targets and 
indicators for 2015. MDG number 6, namely: Combat HIV/AIDS, malaria and 
other diseases includes TB. The target is “To have halted by 2015 and begun 
to reverse the incidence of malaria and other major diseases”. Two related TB 
specific indicators have been specified: 
 
 Incidence, prevalence and death rates associated with tuberculosis 
 Proportion of tuberculosis cases detected and cured under DOTS. This 
is similar to the WHA and Stop TB Partnership targets 
 
1.1.3: Stop TB Partnership targets: 
 
To operationalise the WHA and the MDGs targets, the Stop TB Partnership 
defined a quantitative framework for measuring reduction in TB prevalence 
and death rates. In addition, the Stop TB Partnership committed to eliminate 
TB as a public health problem by 2050. Three targets were set, namely: 
 
                                                
7 World Health Organization. Forty-Fourth World Health Assembly. Resolution WHA44.8. Geneva 
World Health Organization 1991. Report No.: WHA44/1991/REC/1 
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 At least 70% of people with sputum-smear positive TB will be 
diagnosed and at least 85% cured by 2005. These are similar to the 
targets set by the WHA. 
 By 2015, the global burden of TB (per capita prevalence and death 
rates) will be reduced by 50% relative to 1990 levels. 
 The global incidence of TB disease will be less than 1 case per million 
population per year (definition for TB elimination) by 2050. 
 
 
1.1.4: Abuja Declaration and Plan of Action on HIV/AIDS, Tuberculosis 
and Other Related Infectious Diseases (ORID) 8 
 
In April 2001, the African Heads of State and Government met in Abuja at a 
special summit of the Organisation of African Unity (OAU) devoted specifically 
to address the exceptional challenges of HIV/AIDS, Tuberculosis (TB) and 
Other Related Infectious Diseases (ORID). At the end of the Summit, a 
Declaration was adopted that, among others, pledging to set a target of 
allocating 15% of national budgets to the improvement of the health 
sector, and that an appropriate and adequate portion of this amount is put at 
the disposal of authorities for the fight against HIV/AIDS, TB and ORID.  
  
1.1.5: Declaration of TB as an Emergency in the African Region 
 
In August 2005, recalling Resolution AFR/RC44/R6 of September 1994 on 
implementation of Short Course Chemotherapy by TB Control Programmes in 
the region; noting the increasing national and international commitments to 
fight AIDS, tuberculosis and malaria; and noting the increasing financial 
resources made available, among others, by the Global Fund to Fight AIDS, 
Tuberculosis and Malaria, the Stop TB Partnership and bilateral partners; and 
convinced that unless extraordinary actions are undertaken to address the 
current trend the TB epidemic would only get worse; the 55th session of the 
Regional Committee of Ministers of Health of the WHO African Region 
declared TB an emergency in the Region9 and called for urgent and extra-
ordinary actions to rapidly bring the TB epidemic under control. Among other 
actions, the resolution requested Member States to: 
 
 develop and implement with immediate effect emergency strategies 
and plans to control the worsening tuberculosis epidemic; 
 rapidly improve tuberculosis case detection and treatment success-
rates; and  
 accelerate implementation of interventions to combat the TB/HIV 
epidemic, including increased access to ARVs by doubly-infected 
patients; 
 
                                                
8 African Summit on HIV/AIDS, Tuberculosis and other related infectious diseases. Abuja Nigeria. 24-
27 April 2001. OAU/SPS/ABUJA/3 




1.1.6: Special Summit on HIV/AIDS, Tuberculosis and Malaria10  
 
In May 2006, Heads of State and Government of the African Union, held a 
Special Summit on HIV/AIDS, Tuberculosis and Malaria, to review the status 
of implementation of Declarations and Frameworks for Action on the 2000 
Abuja Summit on Roll Back Malaria, and the 2001 Abuja Summit on 
HIV/AIDS, TB and ORID. During the summit, the Heads of Sate and 
Government adopted the “Abuja Call for Accelerated Action towards Universal 
Access to HIV/AIDS, Tuberculosis and Malaria services”11.  
 
The Call collectively resolved dedication to a comprehensive remedial effort 
anchored on an implementation mechanism that addresses the following 
program areas: 
 
i: Leadership at National, Regional and Continental Levels 
ii: Resource mobilisation 
iii: Protection of Human Rights 
iv: Poverty Reduction, Health and Development 
v: Strengthening Health Systems 
vi: Prevention, Treatment , Care and Support 
vii: Access to Affordable Medicines and Technologies 
viii: Research and Development 
ix:  Implementation at national level 
x: Partnerships 
xi: Monitoring , Evaluation and Reporting 
 
1.1.7 The 2007 WHO Regional Committee addresses TB and HIV  
 
Noting that tuberculosis cases have more than trebled in many countries over 
the past 10 years, especially where HIV prevalence is high and recognizing 
the public health importance of the two epidemics, the 57th session of the 
Regional Committee for the African meeting in Brazzaville in August 2007 
adopted a resolution calling for further strengthened and improved 
mechanisms of collaboration between the Tuberculosis and AIDS Control 
Programmes in order to increase prevention, case finding and treatment of TB 
among PLWHA, improve access to HIV Testing and Counselling among TB 
patients and infection control to reduce transmission. 
 
2: Monitoring, Evaluation and Reporting mechanisms for the Call 
 
The Third Session of the African Union Conference on Ministers of Health, 
held from 10-14 April 2007 in Johannesburg, South Africa, agreed on a 
Monitoring and Reporting Mechanism for the Implementation of the 2006 
Abuja Commitments on HIV/AIDS, Tuberculosis and Malaria (ATM) services  
                                                
10 Special Summit of African Union on HIV and AIDS, Tuberculosis and Malaria (ATM). Abuja, 
Nigeria. 2-4 May, 2006. Sp/Assembly/ATM/2(I). Rev 3 
11 Abuja Call for Accelerated Action towards Universal Access to HIV and AIDS, Tuberculosis and 
Malaria services in Africa. Sp/Assembly/ATM/2(I). Rev 3 
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for the period 2007-201012. The framework is based on the programme areas 
agreed by the Heads of State and Government as outlined in section 1.1.5. 
 
2.1: Abuja targets to be met by a United Africa by 2010 
 
Within the agreed monitoring and evaluation Framework for the 
implementation of the Abuja Call, Member States will intensify the fight 
against the three diseases and achieve other internationally agreed goals.  
 
In addition to the WHA, MDG, Stop TB Partnership and Abuja 2001 targets 
outlined in sections 1.1.1-1.1.413, the Summit set the following Tuberculosis 
related specific targets to be achieved by a United Africa by 2010:   
 
 100% of TB patients have access to HIV Testing and counselling 
services 
 100% of eligible HIV positive TB patients access anti-retroviral 
treatment 
 
3: Operating Definitions14: 
 
3.1 Patient classification and categorisation 
 
3.1.1 A case of tuberculosis: A patient in whom TB has been 
bacteriologically confirmed, or has been diagnosed by a clinician. 
 
3.1.2 Pulmonary tuberculosis:  Bacteriologically confirmed TB of the lungs 
(definite TB case) or a case of pulmonary tuberculosis that does not meet the 
bacteriological confirmation criteria but has at least two sputum smears 
negative for TB bacilli, no response to a course of broad spectrum antibiotics 
among those not used in the treatment of TB, radiological abnormalities 
consistent with active pulmonary TB, and a decision by a clinician to treat with 
a full course of anti-tuberculosis chemotherapy. 
 
3.1.3 Extra-pulmonary tuberculosis: Tuberculosis of organs other than the 
lungs for example the pleura of the lungs, lymph nodes, abdomen, genitor-
urinary tract, skin, joints and bones, brain meninges, etc. Diagnosis is based 
on at least one culture-positive specimen, or histological or strong clinical 
evidence consistent with extra-pulmonary tuberculosis, followed by a decision 
by a clinician to treat with a full course of anti-tuberculosis chemotherapy. A 
patient diagnosed with both pulmonary and extra-pulmonary TB is classified 
as a case of pulmonary TB. 
                                                
12 Strengthening of Health Systems for Equity and Development in Africa. Third session of the African 
Union Conference of Ministers of Health, Johannesburg South Africa.  CAMN/MIN/9 (III) 
13 to detect 70% of new smear-positive TB cases arising annually, and to successfully treat 85% of 
these cases; to have halted by 2015 and begun to reverse the incidence of malaria and other major 
diseases; and  WHA and MDG targets plus reducing per capita prevalence and death rates by 50% 
relative to 1990 levels, and reducing TB incidence to les than one case per million population per year 
by 2050 
 





3.1.4 New TB case: A patient who has never been treated with anti-TB 
medicines before or who has previously taken anti-tuberculosis treatment for 
less than one month. 
 
3.1.5 Relapse case: A patient previously treated for TB who was declared 
cured or treatment completed, but is diagnosed with bacteriologically 
confirmed TB again. 
 
3.1.6 Treatment after Failure: A TB patient who is started on re-treatment 
anti-TB regimen after having failed on a previous treatment regimen.  
 
3.1.7 Treatment after default: A TB patient who returns for treatment with 
positive bacteriology, following interruption of treatment for two months or 
more. 
 
3.1.8 Other: All cases which do not fit the above standard definitions.  
 
3.1.9 Case detection rate: proportion of identified TB cases relative to 
estimated existing cases in a referent population. Diagnosis is mainly among 
adults through sputum smear microscopy, culture or any other WHO 
recommended test for the diagnosis of TB. 
  
3.2 Treatment outcomes of bacteriologically confirmed pulmonary TB 
patients: 
 
3.2.1 Cured: A new or re-treatment TB patient who is sputum smear positive 
at the beginning of treatment and is sputum smear /or culture negative in the 
last month of treatment and on at least one previous occasion during the 
course of treatment. 
 
3.2.2 Treatment completed: A patient who has completed treatment but 
who does not meet the criteria to be classified as a cure or a failure. 
 
3.2.3 Treatment success rate: proportion of TB cases on treatment who are 
cured, plus those who have completed treatment but have no bacteriological 
evidence for cure relative to all those smear and or culture positive that 
started treatment during a specified time cohort. 
 
3.2.4 Treatment Failure: A patient who, while on first line or re-treatment 
regimen, is bacteriologically positive at 5 months or later during the course of 
treatment or found to harbour MDR or XDR strain at any point of time during 
the treatment.  
 
3.2.5 TB death: A known TB patient who dies from any cause whilst still on 
TB treatment. 
 
3.2.6 Treatment Defaulter: A patient whose treatment was interrupted for 




3.2.7 Transfer out: A patient who has been transferred to another recording 
and reporting unit and for whom the treatment outcome is not known. 
 
3.3 Drug resistant TB  
 
3.3.1 Multidrug resistant TB (MDR-TB): TB caused by a strain resistant to, 
at least, Isoniazid (H) and Rifampicin ® at the same time. 
 
3.3.2 Extensively drug resistant TB (XDR-TB) : TB caused by a strain that 
is resistant to at least Rifampicin and Isoniazid (i.e. MDR-TB), plus resistance 
to any medicine in the fluoroquinolone family such as Ciprofloxacin and 
Ofloxacin; and also resistance to at least one of the three second line 
injectable anti-TB drugs such as Capreomycin, Kanamycin and Amikacin. 
 
4: Situation Analysis. Report on TB situation in the WHO African 
Region 
 
4.1: Leadership at National, Regional and Continental Levels 
 
Since TB was declared an emergency in the African Region, 18 countries15 
declared TB a national emergency /crisis and implemented special action 
plans to accelerate control. 
 
In August 2007, the 57th session of the Ministers of Health of the African 
Region adopted a Strategy for control of the TB/HIV dual epidemic that 
highlights strengthening of mechanisms for collaboration between TB and 
HIV/AIDS control programmes, improving prevention, case finding and 
treatment of TB among people living with HIV and AIDS, improving access to 
HIV testing and counselling among TB patients, infection control to reduce 
transmission, advocacy, communication and social mobilisation, partnerships 
and resource mobilisation , and research. 
 
During its 46th Conference, Health Ministers of the East, Central and Southern 
African (ECSA) health community in March 2008, adopted among others, a 
resolution on increasing access to medicines and medical supplies that urges 
all member states to develop and implement national medicines policies by 
2009 and review essential drug lists and treatment guidelines at least every 
two years. 
 
4.2 Prevention, Treatment, Care and Support 
 
4.2.1 Trend of TB Notifications  
 
Absolute TB cases notified in the Region have continued to increase every 
year. With approximately only 11% of the world population, the Region 
contributes at over 20% of the global TB burden (Figure 4.21). 
 
                                                
15 Botswana, Burkina Faso, Cote d’ Ivoire, DRC, Guinea Conakry, Kenya, Lesotho, Malawi, Mali, 
Mozambique, Namibia, Nigeria, Senegal, Sierra Leone, South Africa , Tanzania, Togo and Zambia 
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Figure 4.2.1: Proportion of notified TB cases by WHO Region. 2006 
 
Notification rates (per 100,000 population) for all forms of TB have risen from 
82 in 1990 to 160 in 2006. For new smear positive cases, the rates have risen 
from   19 in 1993 to 72 in 2006. At this rate, the MDG targets relative to 1990 
rates are unlikely to be achieved for the entire region (Table 4.2.1). 
 
Table 4.2.1: Trend of TB notification rates by country. African Region  
 
New smear-positive notification rates. African Region 1993–2006 
  Rate (per 100 000 population) 
  1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Algeria   25 20 23 26 25 26 27 26 26 27 26 26 26 
Angola 42 36 31 63 64 55 54 65 83 123 125 130 127 130 
Benin 29 27 30 29 29 29 31 32   31 31 31 32 34 
Botswana 101 109 122 158 172 186 161 179 174 188 170 172 173 175 
Burkina Faso   6 10 13 10 12 12 13 12 12 13 14 16 19 
Burundi 31 25 18 24 32 43 45   44 40 42 43 42 38 
Cameroon 17 14 21 16 24 29 38 25 29 48 63 64 73 76 
Cape Verde     28 28 25 24     30 23 34 34 27 25 
Central 
African 
Republic     52 56 63 71 72   35 69 69 71 51 104 
Chad     28 12     36     39 38 23 25   
Comoros     17 17 16 15 16 12 13 10 6 8 10 8 
Congo   62 72 87 67 67 71 132 131 149 101 117 101 91 
Côte d'Ivoire 50   55 58 57 61 60 50 63 62 64 67 67 68 
DR Congo 35   46 52 52 69 71 71 81 83 97 109 111 105 
Equatorial 
Guinea     57 53 56 69           86     
Eritrea         4 4 15 16 18 16 21 17 15 14 
Ethiopia   10 15 21 25 29 32 44 46 50 53 54 49 45 
Gabon   38 46 24 52 78 79   94 84 99 104 81 87 
Gambia     67 62 66 70 64     70 68 64 70 73 
Ghana   33 15 35 39 40 35 36 37 37 36 33 33 34 
Guinea 31 30 31 38 39 43 44 48 49 51 52 57 61 64 
Guinea-
Bissau     80 75 68 42 53 38   62 64 77 71 63 
Kenya 39 43 51 60 66 81 89 92 98 104 113 119 113 107 















Liberia 75   54 29   44   33 29 61 40 74 63 81 
Madagascar 52 54 58 59   63     67 66 73 75 70 81 
Malawi 58 60 62 65 72 80 72 71 70 63 61 66 64 60 
Mali   20 21 24 35 27 28 25   26 28 27 30 32 
Mauritania     93   107 48 82 62       58 39 49 
Mauritius     10 9 10 9 10 10 7 7 8 10 9 7 
Mozambique 64 63 66 64 66 70 72 73 75 80 82 85 87 87 
Namibia     42 167 184 200 204 213 237 241 279 259 259 262 
Niger 5 21 16   35 31 25 27 30 29 36 34 38 38 
Nigeria 2   9 10 10 11 13 14 18 17 21 24 25 28 
Rwanda     33 35 44 63 56 45 38 45 52 46 45 45 
Sao Tome & 
Principe             22 21 29 29 22 33 32 23 
Senegal   52 60 64 57 56 50 56 57 53 59 56 57   
Seychelles 3   8 14 17 11 12 14 15 11 6 15 9   
Sierra Leone   34 35 54 54 53   55 57 60 60 69 78 81 
South Africa     56 99 125 150 161 167 182 212 247 266 262 272 
Swaziland     69 228     171 172 119 129 144 171 194 224 
Togo 13   20 20 19 18 17 18   21 22 26 29 33 
Uganda 60 72 64 70 76 78 77 70 68 73 75 75 71 68 
UR Tanzania 55 59 67 70 70 74 73 71 71 68 68 69 66 63 
Zambia   107 108 127     114 124 122 150 171 153 129 120 
Zimbabwe 47   76 100 119 117 115 114 120 124 112 112 100 96 
AFR 19 21 36 44 45 51 54 54 59 65 71 75 73 72 
 
 
The increasing absolute notifications and rates notwithstanding, there is a 
tendency towards stabilization of overall rates and decline in new smear 
positive case notification rates since 2004 (Figure 4.2.2). These findings are 
consistent with apparent decline in TB cases globally16.  
 
4.2.2: Estimated Prevalence, incidence and death rates 
 
Relative to MDG targets and basing on 1990 baseline as stipulated in the 
Stop TB Partnership operationalisation of the MDG targets, estimated regional 
TB prevalence, incidence and mortality rates have increased and are unlikely 
to be achieved by 2015 based on current trends (Figure 4.2.2)   
 
However, according to the WHO Global TB Report for 2008, by the end of 
2006, six countries17 had already halted and started to reverse overall and 
smear positive TB incidence as specified in the core MDG targets.  
 
A further 6 countries18 had already halted and started to reverse estimated TB 
prevalence, while four countries, namely, Angola, Comoros, Sao Tome & 
Principe and Seychelles had already halted and started to reverse death rates 
(Table 4.2.2) 
                                                
16 WHO Global TB Report, 2008 
17 Comoros, Ghana, Mali, Mauritius, Sao Tome & Principe and  Seychelles  
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Figure 4.2.2: Trend of notification rates for total and smear positive cases, and absolute rate 
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Table 4.2.2: Estimated Prevalence, Incidence and Mortality Rates (per 
100,000)  
 




Incidence Mortality  
All Forms All Forms Smear +ve All Forms 




















































































































































































































































































































































































































































4.2.3: Status of case detection and treatment success rates 
 
Based on the WHO TB Global Report 2008, as of end 2006, 10 countries19 
had met the World Health Assembly target of 70% case-detection rate, and 8 
countries20  had achieved the 85% treatment-success rate. Only 2 countries 
(Algeria and Benin) had met both targets (Table 4.2.3). 
 
a):  Case detection rates: 
 
At 46%, new smear positive case detection rate for the African Region is still  
far below the 70% target set by the WHA, MDGs and the AU Heads of state 
and Government Call for Universal Access. While increasing overtime during 




b): Treatment Success Rates 
 
At 76%, the treatment success rate (89% of target) for the 2005 new smear 
positive patient cohort falls short of the WHA, MDG, Stop TB Partnership and 
AU UA targets. Only eight countries from the African Region21 have reached 
the target. This compares to two countries in 2001, three countries in 2002, 
                                                
19 Algeria, Angola, Benin, Botswana, Cameroon, Kenya, Lesotho, Madagascar, Namibia, and South 
Africa 
20 Algeria, Benin, Comoros, DR Congo, Eritrea, Gambia, Mauritius and Sierra Leone 
21 Algeria, Benin, Democratic Republic of Congo, Eritrea, Gambia,  Mauritius and  Sierra Leone 
Figure 4.2.3(a): Trend of case detection rate and percentage of target
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four countries in 2003, and eight countries in 2004. A further four countries22 
have attained treatment success rate of 80% and above but below 85%. 
However, treatment success rate has been increasing gradually since 1999  
(Figure 4.2.3(b)). 
 
Table 4.2.3:  Proportion of New smear positive TB cases Detected and Cured 
under DOTS 
Country Case Detection Rate (%) (70% 
target) 
Treatment Success Rate (%) 
(85% target) 
1995 2000 2006 1995 2000 2005 
Algeria  - 126 102 - 87 87 
Angola  - - 76 - 68 72 
Benin  83 86 86 73 - 87 
Botswana 73 75 80 67 77 70 
Burkina Faso 11 17 17 25 60 71 
Burundi 19 - 24 45 80 78 
Cameroon - 31 91 - 77 74 
Cape Verde - - 33 - - 64 
Central African 
Republic 
- - 69 37 57 65 
Chad 36 - - 47 - - 
Comoros 54 49 42 90 93 91 
Congo 69 86 51 - 69 28 
Cote d’Ivoire 50 32 37 68 - 75 
DR Congo 41 48 61 80 78 85 
Equatorial Guinea 85 - - 89 - - 
Eritrea - 42 35 - 76 88 
Ethiopia 15 30 27 61 80 78 
Gabon - - 58 - - 46 
Gambia 74 - 64 76 - 87 
                                                
22 Kenya, Rwanda, United Republic of Tanzania and Zambia 








































Ghana 15 37 38 54 50 73 
Guinea 44 54 55 78 68 72 
Guinea-Bissau - 45 64 - - 69 
Kenya 57 51 70 75 80 82 
Lesotho 59 72 79 47 - 73 
Liberia - 26 55 79 80 76 
Madagascar 52 - 73 55 70 74 
Malawi 42 44 42 71 73 73 
Mali 16 17 26 59 - 75 
Mauritania - - 34 - - 55 
Mauritius 89 90 67 - 93 86 
Mozambique 57 45 47 39 75 79 
Namibia 21 77 83 - 56 75 
Niger - 40 49 - 65 74 
Nigeria 11 12 20 49 79 75 
Rwanda 35 33 27 - 61 83 
Sao Tome & 
Principe 
- - - - - - 
Senegal 62 53 - 44 52 - 
Seychelles - 83 - 89 82 - 
Sierra Leone 28 33 35 69 77 86 
South Africa - 58 71 - 66 71 
Swaziland - - 49 - - 42 
Togo 13 11 19 60 - 71 
Uganda - 48 44 - 63 73 
UR Tanzania 57 49 46 73 78 82 
Zambia - - 53 - - 84 
Zimbabwe - 45 42 - 69 68 
AFR 23 35 46 62 72 76 
 
 
4.2.4: Prevalence of Drug Resistant TB 
 
Drug resistant TB constitutes a silent component of the TB epidemic in the 
region. Until an outbreak of XDR-TB was reported in early 2006, little attention 
was being paid to identification and treatment of drug resistant TB, even 
though evidence shows that it exists everywhere it has been surveyed for. 
 
Regular case notification initiated in 2007 yielded 8,474 MDR-TB cases from 
28 countries. Four countries, namely, Botswana (2 cases), Lesotho (1 case), 
Mozambique (1 case) and South Africa (536) also reported 541 XDR-TB 
cases.  By the end of 2007, there were still 10 Member States without facilities 
for TB culture and drug susceptibility Testing, constituting 78.3% coverage 
with culture and drug susceptibility testing coverage by country. Table 4.2.4 
shows MDR-TB cases notified by country during 2007, and countries’ status 




Table 4.2.4: Notified MDR-TB cases January-December 2007, and status of treatment programmes 
 
Country 
Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec Total Status of treatment 
programme 
Algeria 
                          Present, Govt 
supported 
Angola           2             2 None, ad hoc  
Benin 








                          
Present, GLC 
supported 
Burundi 4 4 2 2 3 2 2 1 4 1 4 2 31 None, ad hoc  
Cameroon 2 7 2 2 1 2 3 0 3 1 0 5 28 None, ad hoc  
Cape Verde                           No C & S lab 
CAR           5             5 None, ad hoc 
Chad                           No C & S lab 
Comoros                           No C & S lab 
Congo 
Brazzaville                           No C & S lab 
Cote d’Ivoire 0 2 1 4 1 6 0 0 0 6 1 0 21 None, ad hoc 
DRC 
10 8 14 17 20 15 22 11 16 11 4 7 155 
Present, GLC 
supported 
Ethiopia 14 10 12 14 14 9 19 12 14 10 9 8 145 None, ad hoc 
Eritrea                           No C & S lab 
Equatorial 
Guinea                           None, ad hoc 
Gabon                           No C & S lab 




Ghana                           None, ad hoc 
Guinea 




                          No C & S lab 
Kenya 
5 7 7 9 7 9 9 8 3 9 4   77 
Being set up, GLC 
supported 
Lesotho             2 17 1 17 5 4 46 Being set up, GLC 
Liberia                           No C & S lab 
Madagascar 0 0 0 0 2 1 0 0 0 0 3 0 6 None. Ad hoc 
Malawi           1             1 None, ad hoc 
Mali 2 2 1 0 1 1 1 4 1 0 0 0 13 Starting, KNCV & Gvt 
Mauritania         3     3         6 None 
Mauritius                           None, Ad hoc  
Mozambique 10 12 9 9 7 27 13 15 6 36 16 3 163 Present, GLC supported 
Namibia                         150 Present, Govt supported 
Niger 0 0 1 0 0 0 0 0 1 0 0 0 2 None, ad hoc 
Nigeria 1 0 2 0 5 1 1 2 1 0 1 2 16 None. Ad hoc 
Rwanda 6 9 12 6 12 13 8 5 13 9 4 8 105 Present, GLC supported 
Sao Tome           1             1 No C & S lab 
Senegal           9             9 None, ad hoc 
Seychelles                           None, ad hoc 
Sierra Leone                           None, ad hoc, NO DST 
South Africa 611 546 671 529 769 748 466 594 722 739 460 514 7369 Present, Gvt supported 
Swaziland                       67 67 Present, Gvt supported 
Togo                         0 None, ad hoc 
Tanzania 
          8             8 
Being set up, GLC pre-
approval stage 
Uganda                       67 67 Present, GLC supported 
Zambia 3 0 4 10 1 0 0 1 0 0 2 5 26 Present, Gvt supported 
Zimbabwe                           None, ad hoc 







4.2.5:  Status of implementation of TB/HIV Interventions 
 
The key Abuja special Summit targets for TB/HIV interventions are to test 
100% of TB patients for HIV and commencing 100% of eligible co-infected TB 
patients on ART. During 2006, only 22% of notified cases (287,945 TB cases) 
were tested for HIV, 150,739 (52.3%) of which tested positive. This compares 
to 11.2% and 52.0% respectively for 2005. By country,  
 
Of those who tested positive, 37.1% were started on Anti-Retroviral Therapy 
(ART), increasing from 27.3% in 2005 but still far short of the 100% target. At 
this rate, the region is unlikely to reach the 100% target by 2010 set by the 
special summit.  
 
However, 11 countries23 recorded ART coverage of 30% and above, ranging 
from 30.8% in Rwanda to 56.9% in Malawi. Zambia with the highest coverage 
in 2005, recorded a 44.3% decline in coverage during 2006. Furthermore, 
89.1% were started on Co-trimoxazole preventive therapy (CPT), a 23.4% 
increase compared to a figure of 72.2% for 2005. Based on this trend, it is 
likely that 100% coverage with this intervention could be achieved by 2010. At 
this rate, Universal access to CPT is likely to be achieved by 2010. Table 




Table 4.2.5:  Status of implementation of key TB-HIV interventions. African Region 2005 and 2006 
Country 
Total cases notified Proportion (%) of 
notified cases 
tested for HIV  
Proportion of 
tested cases 
positive for HIV 
Proportion (%) 
HIV positive put 
on CPT 
Proportion (%) 
HIV positive put 
on ART 
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 
Algeria  21336 21263                 
Angola  38317 54699                 
Benin  3,457 3734 23 88.9 13.8 14.9 0 68.2 0 43.1 
Botswana  10,228 8,519 22.4 53.8 79.8 71.1 0 0 0 0 
Burkina Faso  3,659 4,248 33.2 33.2 46.1 50.8 67.8 65.7 32.4 26.9 
Burundi  6627 6176 0 0             
Cameroon  22,073 24879 0 34.7   38.9   0   0 
Cape Verde  305 276 97.7 97.8 4.7 3 0 100 100 0 
Central African 
Republic  3411 6375 0 0             
Chad  6505   0               
Comoros  112 116 100 100 1.8 1.7 100 0 100 0 
Congo  9959 8600 0 0             
Côte d'Ivoire  20,026 21,145 20.4 27.5 38 36.7 38 55.6 13.9 46.7 
DR Congo 99,558 98,139 1.9 1.3 20.5 14.3 73.6 90.4 0.8 54.3 
Equatorial 
Guinea                      
Eritrea  3612 3136 0 0             
Ethiopia  125,135 123,009 2.6 2.6 41.1 39.8 88.3 85.6 29.4 27.3 
Gabon  2611 3206 7.1 20.1 100 100 100 100 0 0 
Gambia  2120 1881 0 29.2   25.8   0   16.2 
Ghana  12,124 12511 7 17.1 40.3 33.3 100 68.2 36.8 13.9 
Guinea  7090 9076 0 0             
Guinea-Bissau  1816 2161 11 7 55 56.3 100 100 30 50.6 
Kenya  108,401 115,234 14.4 60.1 57.2 52 44 141.2 17.3 42.9 
Lesotho  10,802 13368 1.4 18.8 81.4 88.6 78.7 56.2 0 8.6 
Liberia  3456 4514 3.3 15.2 12.3 14.7 0 0 0 0 
                                                
23 Benin, Cote D’Ivoire, DRC, Guinea Bissua, Kenya, Malawi, Mauritius, Mozambique, Rwanda, 
South Africa and Zambia 
MIN/Sp/AU/CAMH3/6 TB 
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Madagascar  19475 22,517 9 0 0.9   0   0   
Malawi  27,610 27,011 44.3 63.9 69 69.9 91.7 93.2 49.2 56.9 
Mali  4877 5224 0 9.2   14.6   0   0 
Mauritania  2218 2766 0.5 0 0           
Mauritius  127 115 90.6 87 1.7 5 100 80 50 80 
Mozambique  33,718 35632 0 24.2   70.4   17.4   45.9 
Namibia  15894 15,771 16 0 57.5   0   0   
Niger  8224 8755 0 0     42.8   34.2   
Nigeria  66,848 74,225 10.3 10.1 18 20.7 0 0 0 0 
Rwanda  7,680 8,283 65.1 76.1 45.5 40.7 15.3 43.9 12.8 30.8 
Sao Tome & 
Principe 142 153 100 100 3.5 2 0 0 0 0 
Senegal  10120   0               
Seychelles  14   0       100   100   
Sierra Leone  6,930 8208 0 15   8.5   100   0 
South Africa  302,467 341,165 22.5 32.3 51.9 52.8 100 97.9 33 40.1 
Swaziland  8,864 9195 0 20.1   79.9   87.9   19.4 
Togo  2636 2924 0 0             
Uganda  41,809 41,579 25.2 26 71.3 58.9 25.1 23.2 10.1 7.9 
UR Tanzania 64,200 62,100 2.5 11.5 52.1 50.5 61.1 56.9 22.4 25.9 
Zambia  53,267 51,179 2 22.6 56.7 62.2 0 30.6 68.1 37.9 
Zimbabwe  54891 47774 0 0             
AFR 1,254,751 1 310 841 11.2 22 52 52.3 72.2 89.1 27.3 37.1 
 
 
Based on these figures, the proportion of TB cases tested for HIV had 
doubled between 2005 and 2006 but falls far below the Universal Access 
target of 100%.  
 
By country, only Comoros and Sao Tome and Principe had achieved the 
target in both years. Cape Verde and Mauritius consistently tested over 80% 
of notified cases and should easily reach the set target by 2010. Benin, 
Botswana, Ethiopia, Kenya, Malawi and Rwanda are also making sufficient 
progress from year to year to reach the target by 2010. 
 
4.3: Access to essential anti-TB medicines 
 
Uninterrupted supply of first line anti-TB medicines is a basic requirement for 
effective DOTS based TB Control Programmes.  With the set up of the Global 
Drug Facility (GDF) for access to free quality anti-TB first line drugs to all 
DOTS based programmes with a GNP of less than 3,000 USD, the availability 
of first line anti-TB drugs has improved tremendously. By the end of 
December 2007, all 36 eligible countries from the region that applied to the 
GDF secured 3 year first line anti-TB drug grants, including pediatric 
formulations for some countries.  
 
Notwithstanding, latest available information24 indicates that only 69% of 42 
countries that submitted reports had uninterrupted supply of first line anti-TB 
drugs at both the central and peripheral levels during 2006, while 92.8% had 
uninterrupted supply at peripheral level. Since implementation is mostly at 
peripheral level, approximately 7.2% of countries ran out of drugs at some 
point, thereby limiting access to these. This is a significant short fall with 
regard to Universal Access to essential TB treatment.  
 
                                                
24 WHO Global TB Report 2008 
MIN/Sp/AU/CAMH3/6 TB 
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For the treatment of drug resistant TB, of the 26 countries that reported at 
least a case of MDR or XDR-TB during 2007, only 17 countries (65.4%) have 
an organized treatment programme. Even then, except for those supported 
through the GLC, not all patients have access to second line anti-TB drugs.  
As of January 2008, only 9 countries25 had applied and been approved to 
access concessionary priced second line drugs from the Green Light 
Committee (GLC) of the Stop TB Partnership. This facility is available to all 
DOTS based TB Control programmes and should be utilized more widely than 
is currently the case considering the wide spread existence especially of 
MDR-TB cases. 
 
4.4: Resource Mobilization 
 
4.4.1 National financing of TB services 
 
During 2006, 39 of the 46 Member States (84.7%) % provided information on 
Financing TB Control26. These countries represent 93% of estimated TB 
incidence in the Region for that year. TB specific disaggregated data 
mobilized at national level is however not readily available as most 
programmes are implemented within primary health care services.  
 
WHO has since developed a planning and budgeting tool that is designed to 
help countries align their strategic plans and budgets with all the elements of 
the new Stop TB Strategy. During 2007, 35 countries in the African Region 
were introduced to the tool and used it to elaborate programme budgets. This 
is expected to improve the process of budget estimation and expenditure 
accountability in the coming years. 
 
4.4.2 External financing of TB services 
 
During the past five years, external funding for TB control activities has 
increased significantly. The Global Fund to Fight AIDS, TB and Malaria 
(GFATM) has been the single most important source. During rounds 1-7 from 
2002-2007, approximately 953 million USD (37% of total available grants 
global) was approved for TB Control activities in the African Region. This is 
the largest proportion, followed only by the West Pacific Region at 430 Million 
USD (Figure 4.7.1)27. Notwithstanding, this has not been marched with 
spending (Table 4.7.1) and translating into increased case detection and 
treatment success rates. 
 
                                                
25 Burkina Faso, DRC, Guinea Conakry, Kenya, Lesotho, Mozambique, Rwanda, Tanzania (pre-
approval stage) and Uganda  
26 WHO Global TB Control Report  2008 





Table 4.7.1. (attached) shows TB and TB/HIV grants from the GFATM for 




5.1: Leadership at National, Regional and Continental Levels 
 
The 2006 Abuja Call for Universal Access to ATM services by 2010 by a 
United Africa is the most recent indication of stated ultimate political 
leadership for TB Control in the Region. It effectively ratifies continental 
commitment to the World Health Assembly, MDG and Stop TB Partnership 
targets for TB Control. 
 
It also complements the 2001 Abuja Declaration on HIV/AIDS, Tuberculosis 
and other related Infectious diseases, the 2005 Declaration of TB as an 
Emergency in the Region by Ministers of Health of the WHO African Region 
and subsequent declaration of national emergencies by at least 18 countries, 
and is itself complemented by subsequent commitments on TB/HIV and 
related strategies by the declarations of the Ministers of Health of the African 
Region and various regional economic communities in 2007 and 2008. 
 
The stated commitment not withstanding, national financing of health and TB 
Control programmes is still insufficient to support requisite scale up towards 
universal access. To date, the target of “allocating 15% of national budgets to 
the improvement of the health sector” as stated in the 2001 declaration has 
only been achieved by a limited number of countries. Furthermore, a later call 








Figure 4.7.1: Global Fund funding for TB Control by WHO Region in Million US $. 
Rounds 1-7 
AFR, 953 (37%) 
AMR, 179 (7%)






5.2: TB Prevention, Treatment, Care and Support 
 
5.2.1: Estimated Prevalence, incidence and death rates 
 
TB Prevalence and incidence measure the status of the TB epidemic with 
regard to existing cases and new cases occurring in a defined population at a 
point in time or during a defined time period. Both are directly linked to 
programme activity and population coverage with diagnostic and notification 
services. They are also directly linked to programme performance with regard 
to ability to successfully cure those with infectious forms of TB. Their trend 
provides a measure of the burden of tuberculosis on a population. Survey 
based accurate measures of both prevalence and incidence is the best way to 
determine this burden. However, these can be time consuming, costly and 
technically challenging such that they are beyond the routine use of most 
national programmes, even though they are encouraged where feasible.  In 
the absence of such studies, proxy measures are being used by WHO to 
estimate prevalence, incidence and death rates.  
 
Estimated TB prevalence, Incidence and death rates have all continued to 
increase. Absolute notified cases and TB notification rates have also 
continued to increase at regional level. As a case in point, notification rates as 
a proxy for TB prevalence have risen from 82 per 100,000 population in 1990 
(the Stop TB Partnership set reference year for measuring progress towards 
the MDG targets) to 160 in 2006. At this rate, the TB control MDG targets for 
TB incidence and prevalence are unlikely to be achieved at regional level. 
 
However, according to the WHO Global TB Report for 2008, by the end of 
2006, six countries28 had already halted and started to reverse overall and 
smear positive TB incidence as specified in the core MDG targets (without 
reference to the 1990 rates as specified by the Stop TB P[partnership 
operationalisation of the MDG targets). A further 6 countries29 had already 
halted and started to reverse estimated TB prevalence, while four countries, 
namely, Angola, Comoros, Sao Tome & Principe and Seychelles had already 
halted and started to reverse death rates ( Table 4.2.2). 
 
5.2.2: Status of case detection and treatment success rates 
 
Case detection rate: 
Case detection is a function of availability of laboratory services to diagnose 
TB as well as the quality of the services offered. Poorly developed laboratory 
infrastructure, poor equipment, poor personnel skills, poor technique and poor 
interpretation skills all contribute to low case detection rates. In the era of 
HIV/AIDS, an increasing proportion of patients with sputum smear negative 
TB and extra-pulmonary TB has been observed due to the effect of the co-
infection. However, where available, culture and other more specific 
diagnostic methods exist that correct for this atypical presentation. 
 
                                                
28 Comoros, Ghana, Mali, Mauritius, Sao Tome & Principe and  Seychelles  
29 Angola, Benin, Cape Verde, Eritrea, Guinea Bissau and Niger 
MIN/Sp/AU/CAMH3/6 TB 
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At 46%, new smear positive case detection rate for the African Region is still  
significantly below the 70% target set by the WHA, MDGs and the AU Heads 
of state and Government Call for Universal Access. While increasing overtime 
during the past five years, the region is only achieving 65% of the target. 
 
However, based on the WHO TB Global Report 2008, as of end 2006, 10 
countries30 had met the World Health Assembly target of 70% case-detection 
rate, and 8 countries31 had achieved the 85% treatment-success rate. Only 2 
countries (Algeria and Benin) had met both targets (Table 4.2.3). 
 
Treatment Success Rates 
The level of cured patients and the treatment success rate measure the 
effectiveness of a programme to reduce sources of infection in a community. 
This measure is directly affected by the proportion of patients that fail on 
treatment (Treatment Failures), default from treatment (Treatment Defaulters) 
are transferred out to other registration units (Transfer out) or die from any 
cause while on TB treatment. 
  
At 76%, the treatment success rate for the 2005 new smear positive patient 
cohort represents only 89% of WHA, MDG, Stop TB Partnership and African 
Union Universal Access targets.  
 
Only eight countries from the Region32 have reached the treatment success 
target. This compares to two countries in 2001, three countries in 2002, four 
countries in 2003, and eight countries in 2004. A further four countries33 have 
attained treatment success rate of 80% and above but below 85%.  
 
However, treatment success rates have been increasing progressively since 
1999.  
 
5.2.3: Drug Resistant TB 
 
Drug resistant TB is essentially a man made problem arising from causes 
related to the practice of health care workers or the patient. In the former, 
inadequate dosage, improper drug combinations, or incorrect duration of 
treatment are the main causes. In the latter, patient intolerance to some 
drugs, failures to adhere to treatment or defaulting are the commonest 
causes. 
 
Available data shoes that drug resistant TB has emerged as a silent element 
of the TB epidemic in the region. Regular case notification initiated in 2007 
yielded 8,624 MDR-TB cases from 28 countries and 541 XDR-TB cases from 
four countries. 
 
                                                
30 Algeria, Angola, Benin, Botswana, Cameroon, Kenya, Lesotho, Madagascar, Namibia, and South 
Africa 
31 Algeria, Benin, Comoros, DR Congo, Eritrea, Gambia, Mauritius and Sierra Leone 
32 Algeria, Benin, Democratic Republic of Congo, Eritrea, Gambia,  Mauritius and  Sierra Leone 
33 Kenya, Rwanda, United Republic of Tanzania and Zambia 
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By the end of 2007, there were still 10 Member States without facilities to 
identify drug resistant TB cases, translating into 78.3% coverage with culture 
and drug susceptibility testing coverage by country.  
 
Of the 26 countries that reported at least a case of MDR or XDR-TB during 
2007, only 17 countries (65.4%) have an organized treatment programme. As 
of January 2008, only 9 countries34 had applied and been approved to access 
concessionary priced second line drugs from the Green Light Committee 
(GLC) of the Stop TB Partnership. This facility is available to all DOTS based 
TB Control programmes. 
 
5.2.4:  Status of implementation of TB/HIV Interventions 
While the increase in notified TB cases in the region is widespread, it is most 
noticeable where HIV prevalence is high. HIV promotes the progression of TB 
infection to disease while TB is responsible for over 40% of AIDS related 
deaths in the region and is an AIDS defining condition.  Several randomised 
trials have demonstrated the effectiveness of joint tuberculosis and HIV/AIDS 
interventions in reducing morbidity and mortality among dually infected 
persons35 and such interventions are now recommended as standard 
minimum package of care for dually infected persons.               
           
During 2006, only 22% of notified cases were tested for HIV, compared to the 
100% set by the Abuja Summit. However, this represents a 1005 increase in 
coverage compares to 11.2% for 2005.  
 
Of those who tested positive, 37.1% were started on Anti-Retroviral Therapy 
(ART), increasing from 27.3% in 2005. Again this is far less than the 100% 
target. At this rate, the region is unlikely to reach the 100% target by 2010.  
 
However, 11 countries36 recorded ART coverage of 30% and above, ranging 
from 30.8% in Rwanda to 56.9% in Malawi. Furthermore, 89.1% were started 
on Co-trimoxazole preventive therapy (CPT), a 23.4% increase compared to 
72.2% in 2005. At this rate, Universal access to CPT is likely to be achieved 
by 2010.  
 
5.3: Access to essential anti-TB medicines 
 
TB is a bacteriological disease and its treatment if fundamentally anti-
bacterial. Uninterrupted access to effective and high quality anti-TB medicines 
is key to an effective TB control programme and must be ensured. 
 
Overall, availability of first line anti-TB drugs has improved tremendously. By 
the end of December 2007, all 36 eligible countries from the region that 
applied to the GDF secured 3 year first line anti-TB drug grants, including 
pediatric formulations for some countries.  
                                                
34 Burkina Faso, DRC, Guinea Conakry, Kenya, Lesotho, Mozambique, Rwanda, Tanzania (pre-
approval stage) and Uganda  
35 WHO Interim policy on collaborative TB/HIV activities, Geneva, World Health Organisation, 2004 
36 Benin, Cote D’Ivoire, DRC, Guinea Bissau, Kenya, Malawi, Mauritius, Mozambique, Rwanda, 




Notwithstanding, latest available information37 indicates that only 69% of 42 
countries that submitted reports had uninterrupted supply of first line anti-TB 
drugs at both the central and peripheral levels during 2006. This is a 
significant short fall with regard to Universal Access to essential TB treatment.  
 
For the treatment of drug resistant TB, only 65.4% of countries that reported 
some drug resistant TB cases had organized treatment programmes. 
Furthermore, as of January 2008, only 9 countries38 had applied and been 
approved to access concessionary priced second line drugs from the Green 
Light Committee (GLC) of the Stop TB Partnership. This facility is available to 
all DOTS based TB Control programmes and should be utilized more widely 
than is currently the case. 
 
5.4: Resource mobilization 
 
Adequate financial, human and logistic resources are a pre-requisite for 
implementation of TB control activities, as for other health services. Scale up 
towards universal access will entail even more funding and human resources. 
While donor funding provides significant additional resources, the best way to 
ensure sustainability is through allocation of national resources.  
 
There is insufficient information to determine national funding for TB Control 
as most activities are implemented within primary health care services without 
clear ear marking for TB control. 
 
During the past five years, external funding for TB control activities has 
increased significantly. The Global Fund to Fight AIDS, TB and Malaria 
(GFATM) has been the single most important source. During rounds 1-7 from 
2002-2007, approximately 953 million USD (representing 37% of total 
available grants globally) was approved for TB Control activities in the African 
Region. Notwithstanding, this has not been marched with timely spending and 
has not translated into increased case detection and treatment success rates 
all round. 
 
Despite the progress in tuberculosis control, the Region has failed in 
achieving the global targets for tuberculosis control. While DOTS has 
expanded, covering 94% of the regional population and treatment success is 
high (82%), the case detection rate is only 44%. To improve case detection, 
the regional plan to Stop TB was developed as part of the global plan 2006–
2015. The budgetary need for the period of 2006 to 2015 indicated in the Plan 
is US$ 3.1 billion in the Region. Support to countries was enhanced and 
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38 Burkina Faso, DRC, Guinea Conakry, Kenya, Lesotho, Mozambique, Rwanda, Tanzania (pre-





6: Conclusions and Key Recommendations 
6.1: Conclusions 
 
Tuberculosis control in Africa has progressed during the last decade but the 
continent still lags behind on major TB Control targets. Financial resources, 
traditionally a bottleneck for NTPs till the 2000’s, is no longer a major factor as 
GFATM grants, GDF grants (for standard TB treatment), GLC support (for 
drug resistant TB), bilateral donors support and several Partnership 
mechanisms provide technical and financial assistance to cover most needs. 
In order to achieve Universal Access by 2010 and the MDG targets by 2015, 
much remains to be done, especially to: 
 
 Increase treatment success rate for smear positive TB cases: 
through implementation of initiatives to reduce preventable 
unfavourable treatment outcomes such as patient default, transfer out 
and HIV/AIDS related TB deaths  
 Increase case detection rates: through development and 
strengthening of laboratory infrastructure, public private partnerships in 
the delivery of TB services and expanded institutional and community 
DOTS services. 
 Detect, treat and prevent  Drug resistant TB: through surveillance, 
development of culture and DST capability for first line anti-TB drugs, 
and programmatic management of drug resistant TB cases  as part of 
routine NTP activities 
  
 Scale up TB/HIV collaborative activities: especially HIV testing 
among TB patients, Co-trimoxazole and other preventive therapy, and 
ART for eligible dually infected persons 
 
 Address Health Systems Components that affect TB Control 
(laboratory networks, personnel, surveillance, supply systems and 
monitoring and evaluation.     
 
6.2: Key Recommendations 
 
6.2.1 All countries to periodically review their TB Control performance with 
regard to the WHA, MDG and Abuja targets and develop strategies to 
accelerate their attainment; working in close collaboration with national 
and regional stakeholders and the International Community. 
 
6.2.2 Member states to decentralize and strengthen TB laboratory services 
in the public and private sectors to improve case detection and ensure 
quality assured laboratory services in pursuit of Universal Access to 





6.2.3 National TB Control Programmes to prioritize implementation of 
strategies to expand DOTS diagnosis and treatment services with a 
view to rapidly move towards the WHA, MDG, Abuja and Regional 
Committee targets for treatment success and case detection. This 
includes strengthening the capacity of the Health Systems to suspect 
and diagnose Tuberculosis, and to reduce treatment failures, treatment 
defaulters and transfer outs. 
 
6.2.4 All countries with generalized HIV epidemic (5% or higher) in the 
general population to programme and implement in full the Regional 
Strategy for controlling TB-HIV with particular emphasis on universal 
access to HIV testing for TB patients, ART for eligible HIV positive 
patients and other interventions to reduce the burden of TB on People 
Living with HIV & AIDS, and reduce the burden of HIV &AIDS on dually 
infected TB patients.                                                                                                                                                             
 
6.2.5 Member states to allocate sufficient resources to ensure uninterrupted 
supply of first line anti-TB drugs at central and peripheral levels, 
including adequate buffer stocks at the various levels.  
 
6.2.6 For drug resistant TB cases, national programmes to determine the 
burden of MDR-TB and initiate treatment programmes for all confirmed 
cases. National programmes should also mobilize sufficient quality 
assured second line drugs including concessionary priced drugs 
through the Stop TB Partnership Green Light Committee 
 
6.2.7 Member states to respect the pledge to allocate at least 15% of the 
national budget to health development and allocate a sufficient amount 
of that for delivery for TB control interventions. Further, Member States 
to timely expend approved GFATM grants and submit proposals for 
more funding to meet funding gaps for scale up of activities towards 
universal access. 
 
6.2.8 The UN and Other International Organizations and Donor Agencies are 
called upon to continue to mobilize required resources, as well as 
research for new TB drugs and provide technical support to Member 
States. 
 
6.2.9 The African Union and Regional Economic Communities and Health 
Organizations to advocate to national governments in the 10 countries 
without local capability for TB culture and drug susceptibility testing for 
first line anti-TB drugs, to establish this capacity in order to facilitate 
diagnosis and treatment of MDR-TB cases.  In this connection, they 
should also promote regional cooperation. 
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